# Aquestive Therapeutics (TSX:Not available)

> Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies.

## About

Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. With proprietary technologies like PharmFilm® and AdrenaVerse™, the company develops patient-friendly alternatives to inconvenient or invasive therapies, including investigational treatments for anaphylaxis and potentially alopecia areata. Founded in 2005, Aquestive has built a drug delivery platform and has expertise in manufacturing and packaging a wide range of pharmaceutical products.

## Key facts

- **Cash position:** $49.3 million
- **Shares outstanding:** 125,450,119
- **Fully diluted shares:** N/A
- **Warrants:** 375000
- **Options:** N/A
- **Projects:** ["Anaphylm™ (dibutepinephrine) sublingual film is the first orally delivered film formulation of epinephrine in clinical development for the emergency treatment of severe allergic reactions, including anaphylaxis. Developed using both of Aquestive's core technologies (PharmFilm® and AdrenaVerse™), Anaphylm™ is designed to deliver rapid, effective treatment without the need for injection. Compact, portable, and easy to administer, Anaphylm™ begins to dissolve on contact and requires no water or swallowing—ideal for real-world emergencies.","Libervant (diazepam) buccal film is the first and only orally-administered, non-device diazepam product candidate treatment for seizure clusters (also known as acute repetitive seizures) in children ages 2-5 years and in patients 12 and older. Delivered using Aquestive’s proprietary PharmFilm® technology, Libervant is a discreet, mint-flavored film that dissolves when placed inside the cheek, requiring no swallowing, chewing, or additional liquids. It offers a simple, syringe-free alternative to rectal delivery, with consistent absorption and demonstrated ease of use."]
- **Leadership:** Dan Barber (President and Chief Executive Officer), Peter Boyd (Chief People Officer), Melina T. Cioffi, Pharm.D. (Senior Vice President – Regulatory Affairs), Matthew W. Davis, M.D., RPh (Chief Development Officer), Matthew Greenhawt, M.D. (Chief Medical Officer), Cassie Jung (Chief Operating Officer), Sherry Korczynski (Chief Commercial Officer), Ernie Toth (Chief Financial Officer), Thomas A. Zalewski (Chief Legal Officer and Chief Compliance Officer), Gregory B. Brown, M.D. (Chair of the Board, Director and Chief Executive Officer of Menogen, LLC), John Cochran (Director, Partner at Bratton Capital Management L.P., Partner and Chief Operating Officer of Crestline Investors, Inc.), Abigail L. Jenkins (Director, Former President & Chief Executive Officer of Gamida Cell, Ltd.), Julie Krop, M.D. (Director, Chief Medical Officer of DiaMedica Therapeutics, Inc.), Timothy E. Morris (Director, Chief Operating Officer of Humanetics Corporation), Marco Taglietti, M.D. (Director, Chief Executive Officer of NanoNewron)

_Verified data last updated: 2026-05-15_

## Investor FAQ

### [Upcoming catalysts?](https://chat.orbiton.app/aqst/faq/upcoming-catalysts)

Not disclosed in available filings.

### [Latest news?](https://chat.orbiton.app/aqst/faq/latest-news)

Not disclosed in available filings.

## Live AI chat

- https://chat.orbiton.app/aqst/chat
- Investor website: https://aquestive.com/